Sirolimus for progressive or symptomatic epithelioid hemangioendothelioma
Treatments studied
Part of Cancer clinical trials.
This study tests sirolimus for people with a rare blood-vessel cancer called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can control the disease and improve symptoms. It's for people who can't have surgery to remove the cancer and need systemic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of EHE that is progressive or symptomatic and not suitable for curative surgery.
- You must have at least one measurable tumor that can be evaluated for response.
- You must have adequate organ function (kidney, liver, bone marrow, and blood clotting).
- You must have controlled blood sugar and cholesterol levels.
- You must be willing to use effective contraception during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from European hospitals on people with epithelioid hemangioendothelioma (EHE), a rare tumor that grows in blood vessels. Joining this registry helps doctors learn more about the disease and improve care for others.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This trial tests whether adding sirolimus (a medication that calms the immune system) to standard steroid treatment is better than steroids alone for people newly diagnosed with mild autoimmune hemolytic anemia (AIHA). It may help control the disease with fewer side effects.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
Hear when a new Epithelioid Hemangioendothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.